Department of Vermont Health Access  
Pharmacy Benefits Management Program  
DUR Board Meeting Agenda  

September 15th, 2015 6:00 – 8:30 p.m.

1. Executive Session 6:00 - 6:30

2. Introductions and Approval of DUR Board Minutes 6:30 - 6:35  
(Public Comment Prior to Board Action)

3. DVHA Pharmacy Administration Updates 6:35 - 6:40  
   - Updates

4. Medical Director Update 6:40 – 6:45  
   - Clinical Programs Update  
   - Prescriber Comments

5. Follow-up Items from Previous Meetings 6:45 - 7:00  
   - Recommendation on Multiple Benzo data

6. RetroDUR/DUR 7:00 – 7:15  
   - Present data on Hep C adherence  
   - Present plan for testosterone therapy

7. Clinical Update: Drug Reviews 7:15 – 7:45  
(Public comment prior to Board action)

Abbreviated New Drug Reviews  
   - None at this time

Full New Drug Reviews  
   - Afrezza® Inhal (human insulin)(included in review of class)  
   - Arnity Ellipta® Inhal (fluticasone furoate)  
   - Incruse Ellipta® Inhal (umeclidinium bromide)  
   - Movantik® Tab (naloxegol)  
   - Glyxambi® Tab (empagliflozin & linagliptin)(included in review of class)  
   - Hysingla ER® Tab (hydrocodone bitartrate, extended-release)  
   - Savaysa® Tab (edoxaban)  
   - Cosentyx® Inj (secukinumab)  
   - Rytary® Cap (carbidopa & levodopa, extended-release)  
   - Toujeo® Inj (insulin glargine U-300) (included in review of class)  
   - Eykeko Tab (amphetamine sulfate)  
   - Asmanex HFA® Inhal (mometasone)  
   - Pazeo® OP Sol (olopatadine)  
   - Daklinza® Tab (daclatasvir) (included in review of class)  
   - Technivie® Tab (ombitasvir/paritaprevir/ritonavir) (included in review of class)  
   - Orkambi ® Tab (lumacaftor/ivacaftor)
8. Therapeutic Drug Classes – Periodic Review (Public comment prior to Board action)
   - Hypoglycemics, Incretin Mimetics/Enhancers & SGLT-2 Inhibitors
   - Hypoglycemics, Insulins
   - Hypoglycemics, Meglitinides
   - Hypoglycemics, TZD Agents
   - Alpha 1 proteinase inhibitors
   - Sedative Hypnotics
   - Hepatitis C Treatments
   - Movement Disorder Agents

9. New Managed Therapeutic Drug Classes (Public comment prior to Board action)

10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products (Public comment prior to Board action)

11. General Announcements (Public comment prior to Board action)

   Selected FDA Safety Alerts
   - Non-aspirin Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Drug Safety Communication - FDA Strengthens Warning of Increased Chance of Heart Attack or Stroke
   - Unapproved Prescription Ear Drop (Otic) Products: Not FDA Evaluated for Safety, Effectiveness and Quality
   - FDA Issues the Drug Supply Chain Security Act (DSCSA) Implementation: Product Tracing Requirements for Dispensers–Compliance Policy Guidance
   - FDA Drug Safety Communication: FDA reporting permanent skin color changes associated with use of Daytrana patch (methylphenidate transdermal system) for treating ADHD
   - Brintellix (vortioxetine) and Brilinta (ticagrelor): Drug Safety Communication - Name Confusion
   - Picato (ingenol mebutate) Gel: Drug Safety Communication - FDA Warns of Severe Adverse Events, Requires Label Changes
12. Adjourn  8:30